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[57] ABSTRACT 
The present invention relates to monoclonal antibody 1A7. 
This is an anti-idiotype produced by immunizing With an 
antibody speci?c for ganglioside GD2, and identifying a 
hybridoma secreting antibody With immunogenic potential 
in a multi-step screening process. Also disclosed are poly 
nucleotide and polypeptide derivatives based on 1A7, 
including single chain variable region molecules and fusion 
proteins, and various pharmaceutical compositions. When 
administered to an individual, the 1A7 antibody overcomes 
immune tolerance and induces an immune response against 
GD2, Which comprises a combination of anti-GD2 antibody 
and GD2-speci?c T cells. The invention further provides 
methods for treating a disease associated With altered GD2 
expression, particularly melanoma, neuroblastoma, glioma, 
soft tissue sarcoma, and small cell carcinoma. Patients Who 
are in remission as a result of traditional modes of cancer 
therapy may be treated With a composition of this invention 
in hopes of reducing the risk of recurrence. 
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Fi re3A 
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i e 3 C 
*WW‘A-k ~k~k*-k** 
VL consensus: 1 DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKKGOSPKLLIYFVSNRF 60 
1A7: 1 .......................................... ..P....N ........ .. 60 
* ~k~k-k****** 
VL consensus: 61 SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPWTFGGGTKLEIK 112 
1A7: 61 .................................................. .. 112 
*~k‘k** **~k*~k*~k~k*k** 
VH consensus: 1 QVQLKESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPGKGLEWLGVIWGDGSTNYN 60 
1A7: 1 ...V.....F..P ............... ..T...S.I .......... ..A.....T...H so 
**~k** ***~k******* 
VH consensus: 61 SALKSRLSISKDNSKSQVFLKMNSLQTDDTARYYCAREXXXXYYAMDYWGQGTSVTVSS 119 
1A7: 61 ...I . . . . . . . . . . . . . . . ..L . . . . . . . ..T....KL--GN.D.L . . . . . . . . . . . .. 117 
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Figure 4 
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Figure 6 
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Figure 8 
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Figure 9 
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